Search This Blog

Monday, October 28, 2019

BrainStorm up premarket on positive NurOwn safety review

Thinly traded nano cap BrainStorm Cell Therapeutics (NASDAQ:BCLI) is up 14% premarket on light volume in reaction to the successful outcome of the second safety analysis of NurOwn in a Phase 3 study in ALS patients.
No safety issues were noted by the Data Safety Monitoring Board and the trial will continue as planned. Topline data should be available in Q4 2020.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)